ClinicalTrials.gg
Active, not recruitingNCT07494656Updated Nov 6, 2026

A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany

An observational study in ATTR-CM (Transthyretin Amyloid Cardiomyopathy), sponsored by Pfizer. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Pfizer · Observational

Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1
Ages
18 Years and older
Sex
All
01

Study summary

This observational study aims to describe the characteristics, health outcomes, and epidemiology of individuals diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) in Germany.

ATTR-CM is a rare and serious heart disease caused by the buildup of an abnormal protein called transthyretin in the heart muscle. This can lead to heart failure and other cardiovascular complications.

This is a retrospective, non-interventional study based on anonymized statutory health insurance claims data from Germany. The study includes adults with a new diagnosis of ATTR-CM identified between 2020 and 2022. Data from both inpatient and outpatient healthcare settings are analyzed. No participants are recruited, and no medical treatments, procedures, or study visits are assigned as part of this study.

The study will describe overall survival, cardiovascular-related hospitalizations, and the incidence of ATTR-CM in Germany. A predefined subgroup of individuals with at least one documented prescription for tafamidis will be analyzed separately to describe outcomes in this population.

In addition, the study will examine the use of genetic testing after diagnosis and describe patient characteristics, as observed in routine clinical care.

By using nationwide healthcare data, this study aims to provide a comprehensive and recent real-world overview of ATTR-CM in Germany and to support a better understanding of the disease.

02

Conditions studied

  • ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adults insured under the German statutory health insurance system who were newly identified with transthyretin amyloid cardiomyopathy (ATTR-CM) between 2020 and 2022.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18 years or older at the time of the index date

Individuals with a newly identified transthyretin amyloid cardiomyopathy (ATTR-CM) diagnosis between January 2020 and December 2022, identified using a validated claims-based algorithm

Evidence of amyloidosis, defined as:

At least one inpatient diagnosis or At least two outpatient diagnoses in separate quarters

Evidence of cardiac involvement, defined as at least one diagnosis of cardiomyopathy or heart failure occurring within a defined temporal window before or after the amyloidosis diagnosis

Continuous enrollment in German statutory health insurance for:

At least 8 quarters prior to the index date, and At least 4 consecutive quarters after the index date (or until death)

Exclusion criteria

Exclusion Criteria:

Evidence of light-chain (AL) amyloidosis, including:

AL-specific treatment prescriptions Chemotherapy associated with amyloidosis Diagnosis of multiple myeloma stem cell transplantation

Diagnosis of amyloid angiopathy

Prior amyloidosis diagnosis during the 2-year before the index date Missing or implausible information on sex

Additional Criteria for Tafamidis Subgroup At least one prescription of tafamidis 61 mg during follow-up No prescriptions for other disease-modifying therapies for transthyretin amyloidosis with polyneuropathy

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1 participant (actual)
Patient registry
No

Groups and cohorts

  • Patients with incident transthyretin amyloid cardiomyopathy (ATTR-CM) in Germany

    Adult patients (≥18 years) with incident transthyretin amyloid cardiomyopathy (ATTR-CM) in Germany, identified using a claims-based algorithm in nationwide statutory health insurance data. Incident cases are defined based on a washout period of at least two years without prior amyloidosis diagnosis. Patients are followed from the date of ATTR-CM diagnosis. Subset of the incident ATTR-CM population with at least one documented prescription of tafamidis 61 mg during follow-up will be included.

    Other: tafamidis 61mg (based on prescription data)

Interventions

  • Othertafamidis 61mg (based on prescription data)

    As provided in real world practice

06

What researchers measure

Primary outcomes

  1. Overall Survival in Individuals With Incident Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Overall and in Those With at Least One Tafamidis Prescription

    Time frame: From incident ATTR-CM diagnosis (Index 1) until death, end of SHI enrollment, or end of data availability (December 31, 2023). For those with at least one tafamidis prescription, additionally from first tafamidis prescription (Index 2).

  2. Cardiovascular-Related Hospitalizations in Individuals With Incident Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Overall and in Those With at Least One Tafamidis Prescription

    Time frame: From incident ATTR-CM diagnosis (Index 1) until death, end of SHI enrollment, or end of data availability (December 31, 2023). For those with at least one tafamidis prescription, additionally from first tafamidis prescription (Index 2).

Secondary outcomes

  1. Annual Incidence of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Germany

    Time frame: Calendar years 2020, 2021, and 2022

07

Study locations

1 site
  • Pfizer
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 27, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Nov 30, 2026was Sep 2026
CompletionEst.
Nov 30, 2026was Sep 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Nov 30, 2026
Nov 6, 2026
Study completion
Sep 30, 2026→Nov 30, 2026
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Sep 30, 2026→Nov 30, 2026
    Study completion Sep 30, 2026→Nov 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07494656
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Apr 2, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion